These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24747288)

  • 1. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
    Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
    Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.
    Sharma MK; Murumkar PR; Barmade MA; Giridhar R; Yadav MR
    Expert Opin Ther Pat; 2015; 25(10):1093-116. PubMed ID: 26161824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
    Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
    Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.
    Sharma MK; Murumkar PR; Giridhar R; Yadav MR
    Mol Divers; 2015 Nov; 19(4):871-93. PubMed ID: 26183840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?
    Bermudez-Silva FJ; Viveros MP; McPartland JM; Rodriguez de Fonseca F
    Pharmacol Biochem Behav; 2010 Jun; 95(4):375-82. PubMed ID: 20347862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
    Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.
    Lee HK; Choi EB; Pak CS
    Curr Top Med Chem; 2009; 9(6):482-503. PubMed ID: 19689362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptor antagonists and obesity.
    Black SC
    Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reports of the death of CB1 antagonists have been greatly exaggerated: recent preclinical findings predict improved safety in the treatment of obesity.
    McLaughlin PJ
    Behav Pharmacol; 2012 Sep; 23(5-6):537-50. PubMed ID: 22743603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
    Zhu B; Matthews JM; Xia M; Black S; Chen C; Hou C; Liang Y; Tang Y; Macielag MJ
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5597-5601. PubMed ID: 27671499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
    Giraldo J
    Drug Discov Today; 2010 Jun; 15(11-12):411-5. PubMed ID: 20447467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.